Self-sampling for Non-attenders to Cervical Cancer Screening (KOPRETINA)

Cervical Cancer Prevention Using Self-sampling and Human Papillomavirus Detection

The trial will evaluate whether self-sampling and human papillomavirus (HPV) testing may increase cervical cancer screening attendance among under-screened women in Czech Republic. Different ways of offering self-sampling device will be evaluated.

Study Overview

• Status: Recruiting
• Conditions: Cervical Cancer; Human Papillomavirus Infection; Cervical Dysplasia
• Intervention / Treatment: Diagnostic test: Self-sampling by Evalyn Brush; Diagnostic test: Self sampling by Evalyn Brush home or in GP´s clinic

Detailed Description

Despite the existence of an effective cervical cancer screening in the Czech Republic, cervical cancer is the cause of about 800 new cases and 400 deaths every year. One of the major problem of the Czech cervical cancer screening is low participation. An effective strategy to increase cervical cancer screening attendance is one of the main challenges. The offering of self-sampling to the cervical cancer screening non-attenders could increase women's participation as was shown in several European countries.

The trial should determine acceptability of the self-sampling followed by HPV DNA test by Czech women and therefore usability of the self-sampling device to increase cervical cancer screening attendance among under-screened women. Three different approaches will be tested: women will receive a self-sampling device by mail (Arm A); receive a self-sampling device by gynecologist (Arm B); receive a self-sampling device by general practitioner (Arm C). Comparisons of the screening attendance among the arms will be made. To address also potential effects on inequities, the analyses will include comparisons by sociodemographic characteristics. Women from the database of commercial vendor will be included to the Arm A regardless of whether or not they participate in cervical cancer screening program. Women who do not participate in cytology-based cervical cancer screening program for at least three years will be included through their gynecologist (Arm B) or general practitioner (Arm C) database.

The second focus of the trial is the evaluation of high-risk human papillomavirus prevalence in screening population of Czech women (attenders and non-attenders of cervical cancer screening) since there are no relevant data for the Czech Republic. Study participants may volunteer for archiving of remaining biological materials for future studies.

• Study Type: Interventional
• Enrollment (Estimated): 15000
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Marian Hajduch, MD, PhD.; Phone Number: +420 585 632 083; Email: marian.hajduch@upol.cz
• Study Contact Backup: Name: Vladimira Koudelakova, MSc, Ph.D.; Phone Number: +420 585 632 089; Email: vladimira.koudelakova@upol.cz

Study Locations

• Czechia
  • Olomouc, Czechia
    • Recruiting
    • University Hospital Olomouc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Women with age 30-65 years; for arm A women > 65 years are allowed
• Women live in the Czech Republic.
• Women who have not participate in cervical cancer screening program in the Czech Republic for at least 3 years (Arm B and C).
• Women with completed informed consent.
• Women capable of self-sampling of cervicovaginal swab.

Exclusion Criteria:

• Pregnant women.
• Women with no sexual intercourse experience.
• Women after hysterectomy including cervix.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Self-sampling device sent at home; Women randomly selected from a commercial vendor database (both attenders and non-attenders) receive a mail inviting them to perform a cervicovaginal self-sampling at their home (with the device provided). Returned self-sampled swabs will be tested by CE-IVD-marked (Conformité Européenne, In Vitro Diagnostics) HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.	Diagnostic test: Self-sampling by Evalyn Brush; Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.
Experimental: Self-sampling device sent by gynecologist(s); Women selected from databases of cooperating gynecologists (non-attenders for at least 3 years) receive a mail inviting them to perform a cervicovaginal self-sampling at their home (with the device provided). Returned self-sampled swabs will be tested by CE-IVD-marked HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.	Diagnostic test: Self-sampling by Evalyn Brush; Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.
Experimental: Self-sampling device obtained from general practitioner(s); Women selected from databases of cooperating general practitioners (non-attenders for at least 3 years) receive a self-sampling device. Returned self-sampled swabs will be tested by CE-IVD-marked HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.	Diagnostic test: Self sampling by Evalyn Brush home or in GP´s clinic; Women will perform a cervicovaginal self-sampling at their home or the GP´s clinic using Evalyn Brush

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Screening participation	Comparison of the percentages of women who return a cervicovaginal swab sampled by self-sampling device in different arms of the study. Identification of the best approach to address women who do not participate in standard cervical cancer screening program	12 months
Prevalence of high-risk HPV	Evaluation of the prevalence of high-risk human papillomavirus infection in screening population of Czech women within different arms of the study (attenders/non-attenders).	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sociodemographic characteristics	Comparison the distribution of sociodemographic characteristics (education, age, place of residence) and reasons for previous non-attendance for screening by intervention and attendance status in women who return a questionnaire.	12 months

Collaborators and Investigators

• Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic
• Collaborators: National Institute for Cancer Research, Czech Republic
• Investigators: Study Director: Marian Hajduch, MD, PhD., IMTM, Palacky University in Olomouc, Faculty of Medicine and Dentistry

Study record dates

Study Major Dates

• Study Start (Actual): September 23, 2019
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: January 9, 2020
• First Submitted That Met QC Criteria: January 9, 2020
• First Posted (Actual): January 13, 2020

Study Record Updates

• Last Update Posted (Actual): March 23, 2026
• Last Update Submitted That Met QC Criteria: March 19, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: HPV; human papillomavirus; self-sampling; cervical cancer screening; cervicovaginal swab; non-attendance
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Pathologic Processes; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Disease Attributes; Infections; Virus Diseases; Uterine Diseases; Genital Diseases, Female; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; DNA Virus Infections; Genital Neoplasms, Female; Precancerous Conditions; Uterine Cervical Diseases; Uterine Neoplasms; Tumor Virus Infections; Pathological Conditions, Signs and Symptoms; Uterine Cervical Neoplasms; Papillomavirus Infections; Uterine Cervical Dysplasia
• Other Study ID Numbers: 5850

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No